Drug Trial Radar · NCT04516564
A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Sep 28, 2020
Primary completion
May 4, 2021
Study completion Jun 21, 2021
Sponsor
- Lead sponsor
- Akesobio Australia Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH), Phase 1, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, PK and immunogenicity of AK119, a humanized monoclonal antibody targeting the CD73. The study will consist of 4 cohorts of healthy subjects. Eight subjects will be enrolled per cohort, randomized in a 3:1 ratio to receive a single dose of either the active drug AK119 (N=6) or matching placebo (N=2). Approximately 32 subjects (24 receiving active drug and 8 receiving placebo) will participate in this study.
Conditions
- Coronavirus Disease 2019 (COVID-19)
Interventions
AK119Drug
Single dose of AK119 is administered via intravenous infusion to healthy subjects
PlaceboDrug
Single dose of placebo is administered via intravenous infusion to healthy subjects
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent AEsTime frame: From signing of informed consent till end of study (approximately 64 days postdose)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Christchurch Clinical Studies Trust
Christchurch, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.